Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update
01 août 2019 16h05 HE
|
Kura Oncology, Inc.
- Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing – – Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration – –...
Kura Oncology to Report Second Quarter 2019 Financial Results
25 juil. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
24 juil. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents
11 juil. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
21 juin 2019 16h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 21, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
18 juin 2019 23h31 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Commencement of Public Offering of Common Stock
18 juin 2019 16h01 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference
08 mai 2019 08h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
07 mai 2019 16h05 HE
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA...
Kura Oncology to Report First Quarter 2019 Financial Results
30 avr. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...